Clinical outcomes after IL-6 blockade in patients with COVID-19 and HIV: a case series

BACKGROUND: In hospitalized people with HIV (PWH) there is an increased risk of mortality from COVID-19 among hospitalized PWH as compared to HIV-negative individuals. Evidence suggests that tocilizumab—a humanized monoclonal interleukin (IL)-6 receptor inhibitor (IL-6ri) antibody—has a modest morta...

Descripción completa

Detalles Bibliográficos
Autores principales: Minkove, Samuel J., Geiger, Grant, Llibre, Josep M., Montgomery, Mary W., West, Natalie E., Chida, Natasha M., Antar, Annukka A. R., Dandachi, Dima, Weld, Ethel D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832430/
https://www.ncbi.nlm.nih.gov/pubmed/35148782
http://dx.doi.org/10.1186/s12981-022-00430-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832430/
https://www.ncbi.nlm.nih.gov/pubmed/35148782
http://dx.doi.org/10.1186/s12981-022-00430-x

Ejemplares similares